SAN DIEGO, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today a worldwide, nonexclusive license to Bristol-Myers Squibb Company (NYSE:BMY) of Vical's patented platform DNA immunization technology and its Vaxfectin® adjuvant for use in the production of antibodies.